{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:30:06Z","timestamp":1780475406952,"version":"3.54.1"},"reference-count":56,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World j. surg."],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is uncertainty in the relative benefits and harms of hyperthermic intraoperative peritoneal chemotherapy (HIPEC) when added to cytoreductive surgery (CRS) +\/\u2212 systemic chemotherapy or systemic chemotherapy alone in people with peritoneal metastases from colorectal, gastric, or ovarian cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched randomized controlled trials (RCTs) in the medical literature until April 14, 2022 and applied methods used for high\u2010quality systematic reviews.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>We included a total of eight RCTs (seven RCTs included in quantitative analysis as one RCT did not provide data in an analyzable format). All comparisons other than ovarian cancer contained only one trial. For gastric cancer, there is high uncertainty about the effect of CRS\u00a0+\u00a0HIPEC\u00a0+\u00a0systemic chemotherapy. For stage III or greater epithelial ovarian cancer undergoing interval cytoreductive surgery, CRS\u00a0+\u00a0HIPEC\u00a0+\u00a0systemic chemotherapy probably decreases all\u2010cause mortality compared to CRS\u00a0+\u00a0systemic chemotherapy. For colorectal cancer, CRS\u00a0+\u00a0HIPEC\u00a0+\u00a0systemic chemotherapy probably results in little to no difference in all\u2010cause mortality and may increase the serious adverse events proportions compared to CRS +\/\u2212 systemic chemotherapy, but probably decreases all\u2010cause mortality compared to fluorouracil\u2010based systemic chemotherapy alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>The role of CRS\u00a0+\u00a0HIPEC in gastric peritoneal metastases is uncertain. CRS\u00a0+\u00a0HIPEC should be standard of care in women with stage III or greater epithelial ovarian cancer undergoing interval CRS. CRS\u00a0+\u00a0systemic chemotherapy should be standard of care for people with colorectal peritoneal metastases, with HIPEC given only as part of a RCT focusing on subgroups and regimes.<\/jats:p><\/jats:sec><jats:sec><jats:title>PROSPERO Registration<\/jats:title><jats:p>CRD42019130504.<\/jats:p><\/jats:sec>","DOI":"10.1002\/wjs.12186","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T01:13:07Z","timestamp":1714007587000},"page":"1385-1403","source":"Crossref","is-referenced-by-count":10,"title":["Cytoreductive surgery plus hyperthermic intraoperative peritoneal chemotherapy for people with peritoneal metastases from colorectal, ovarian or gastric origin: A systematic review of randomized controlled trials"],"prefix":"10.1002","volume":"48","author":[{"given":"Kurinchi","family":"Gurusamy","sequence":"first","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-9702","authenticated-orcid":false,"given":"Jeffrey","family":"Leung","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Vale","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Roberts","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Linden","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Wei","family":"Tan","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyal","family":"Taribagil","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam","family":"Patel","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pizzo","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Davidson","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Saunders","sequence":"additional","affiliation":[{"name":"The Colorectal and Peritoneal Oncology Centre Christie NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Aziz","sequence":"additional","affiliation":[{"name":"The Colorectal and Peritoneal Oncology Centre Christie NHS Foundation Trust  London UK"},{"name":"Division of Cancer Studies University of Manchester  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[{"name":"The Colorectal and Peritoneal Oncology Centre Christie NHS Foundation Trust  London UK"},{"name":"Division of Cancer Studies University of Manchester  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"e_1_2_15_2_1","unstructured":"International Agency for Research on Cancer (World Health Organization).2017. \u201cEstimated Number of Incident Cases Both Sexes All Cancers Excluding Non\u2010melanoma Skin Cancer Worldwide in 2012.\u201d.https:\/\/gco.iarc.fr\/today\/online\u2010analysis\u2010table?mode=cancer&mode_population=continents&population=900&sex=0&cancer=29&type=0&statistic=0&prevalence=0&color_palette=default. accessed on 3rd December 2017."},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25596"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep29765"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.8679"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.10.001"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.01.017"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28373"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/dcr.0000000000000412"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.03.277"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010014\u20104157\u20109"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.01.018"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010008\u20109966\u20102"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.09.024"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.030"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010015\u20104853\u20100"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2014.08.477"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17497"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.5301\/tj.5000623"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.04.023"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2010.03.005"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20104733.2007.00249.x"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0b013e3181c9b53c"},{"issue":"1","key":"e_1_2_15_24_1","article-title":"Is Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Cost\u2010Effective for Metastatic Colorectal Cancer?","volume":"23","author":"Lee Z.","year":"2016","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_15_25_1","article-title":"Cytoreductive Surgery and Intraperitoneal Chemotherapy (HIPEC or EPIC) in Patients with Colorectal Adenocarcinoma and Peritoneal Carcinomatosis. (Structured Abstract)","volume":"4","author":"Ludwigs K.","year":"2013","journal-title":"Health Technology Assessment Database"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24162"},{"issue":"4","key":"e_1_2_15_27_1","first-page":"776","article-title":"The Cost of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy in the Treatment of Peritoneal Malignancy in One Greek Institute","volume":"17","author":"Tentes A. A. K.","year":"2012","journal-title":"Journal of B.U.ON."},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010009\u20100487\u20104"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102168.2000.01538.x"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1515\/pp\u20102016\u20100010"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23189"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000000179"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1515\/pp\u20102016\u20100027"},{"issue":"11","key":"e_1_2_15_34_1","first-page":"20562","article-title":"Cytoreductive Surgery Combined with Intraperitoneal Chemotherapy in the Treatment of Colorectal Peritoneal Metastasis: A Meta\u2010Analysis","volume":"9","author":"He T. F.","year":"2016","journal-title":"International Journal of Clinical and Experimental Medicine"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/igc.0000000000000664"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.08.172"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2016.09.002"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i38.14018"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2018.05.006"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24813"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.06.005"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_15_43_1","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations","author":"Sch\u00fcnemann H. B. J.","year":"2013"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102020\u2010039314"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010011\u20101631\u20105"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1485"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23633"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010021\u201011087\u20107"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0143"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708618"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30599\u20104"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.04.187"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo\u20102020\u201005"},{"key":"e_1_2_15_54_1","unstructured":"Medica AIdO.2023. \u201cTUMORI PERITONEALI PRIMITIVI E SECONDARI: Associazione Italiana di Oncologia Medica.\u201d: Available from.https:\/\/snlg.iss.it\/wp\u2010content\/uploads\/2022\/01\/LG\u2010457\u2010AIOM_Peritoneo.pdf. Accessed 27 February 2023."},{"key":"e_1_2_15_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"e_1_2_15_56_1","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","author":"Morris V. K.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_15_57_1","volume-title":"Bowel cancer survival statistics","author":"UK CR","year":"2023"}],"container-title":["World Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/wjs.12186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T01:52:29Z","timestamp":1717725149000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/wjs.12186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/wjs.12186"],"URL":"https:\/\/doi.org\/10.1002\/wjs.12186","archive":["Portico"],"relation":{},"ISSN":["0364-2313","1432-2323"],"issn-type":[{"value":"0364-2313","type":"print"},{"value":"1432-2323","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]}}}